During the last session, UroGen Pharma Ltd (NASDAQ:URGN)’s traded shares were 0.74 million, with the beta value of the company hitting 0.69. At the end of the trading day, the stock’s price was $9.67, reflecting an intraday loss of -6.93% or -$0.72. The 52-week high for the URGN share is $20.70, that puts it down -114.06 from that peak though still a striking 7.55% gain since the share price plummeted to a 52-week low of $8.94. The company’s market capitalization is $445.73M, and the average intraday trading volume over the past 10 days was 0.52 million shares, and the average trade volume was 391.37K shares over the past three months.
UroGen Pharma Ltd (URGN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.25. URGN has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.8.
UroGen Pharma Ltd (NASDAQ:URGN) trade information
UroGen Pharma Ltd (URGN) registered a -6.93% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -6.93% in intraday trading to $9.67, hitting a weekly high. The stock’s 5-day price performance is 2.98%, and it has moved by -17.07% in 30 days. Based on these gigs, the overall price performance for the year is -33.26%. The short interest in UroGen Pharma Ltd (NASDAQ:URGN) is 5.65 million shares and it means that shorts have 12.86 day(s) to cover.
The consensus price target of analysts on Wall Street is $40, which implies an increase of 75.83% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $22 and $60 respectively. As a result, URGN is trading at a discount of -520.48% off the target high and -127.51% off the low.
UroGen Pharma Ltd (URGN) estimates and forecasts
In the rating firms’ projections, revenue will increase 34.62% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 22.7M as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 24.66M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 18.78M and 21.85M respectively. In this case, analysts expect current quarter sales to grow by 20.89% and then jump by 12.85% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 10.39%. While earnings are projected to return 1.29% in 2025.
URGN Dividends
UroGen Pharma Ltd is due to release its next quarterly earnings on 2025-Mar-09. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
UroGen Pharma Ltd (NASDAQ:URGN)’s Major holders
UroGen Pharma Ltd insiders own 8.40% of total outstanding shares while institutional holders control 87.25%, with the float percentage being 95.26%. RTW INVESTMENTS, LP is the largest shareholder of the company, while 193.0 institutions own stock in it. As of 2024-06-30, the company held over 3.56 million shares (or 9.661% of all shares), a total value of $59.69 million in shares.
The next largest institutional holding, with 3.3 million shares, is of ADAGE CAPITAL PARTNERS GP, L.L.C.’s that is approximately 8.9621% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $55.37 million.
Also, the Mutual Funds coming in first place with the largest holdings of UroGen Pharma Ltd (URGN) shares are iShares Trust-iShares Russell 2000 ETF and Fidelity Salem Street Trust-Fidelity Small Cap Index Fund . Data provided on Mar 31, 2025 indicates that iShares Trust-iShares Russell 2000 ETF owns about 998.29 shares. This amounts to just over 2.17 percent of the company’s overall shares, with a $9.65 million market value. The same data shows that the other fund manager holds slightly less at 375.71, or about 0.82% of the stock, which is worth about $3.63 million.
